The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies
Global Heart · 16.06.2025 · 20 (1) · 53
DOI: 10.5334/gh.1440 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Global Heart, online erschienen am 16.06.2025. Verfasst von Gang Fan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department of Xianyang Central Hospital, Xianyang, Shaanxi Province, 712000, PR China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Chemotherapy-induced cardiotoxicity is the leading cause of non-tumorrelated mortality among patients with tumors. Although sodium glucose cotransporter 2 inhibitors (SGLT2is) have been shown to confer cardiovascular benefits, their effects and safety profile in patients with cancer remain uncertain. The objective of this study was to assess the cardiovascular effects of SGLT2is in patients with cancer.
Objective
We conducted a meta-analysis of cohort studies to compare the efficacy and safety of SGLT2is and placebo in patients with cancer.
Results
A total of ten cohort studies, encompassing 85,185 patients, were included in this study. SGLT2is significantly decreased mortality (Risk ratios (RR) 0.52, 95% confidence interval (CI) (0.36, 0.75), I2 = 98%), heart failure (HF) (RR 0.43, 95% CI 0.24, 0.77, I2 = 75%), and arrhythmia (RR 0.33, 95% CI 0 .23, 0.49, I2 = 0%). In addition, SGLT2is decreased the incidence of adverse events. No significant difference was identified in hypoglycemia, ketoacidosis, and acute coronary syndrome (ACS).
Conclusion
The present study suggest that sodium glucose cotransporter 2 inhibitors may be an efficacious and safe means for improving the prognosis of patients with cancer and diabetes. However, future large-scale randomized controlled trials are needed to further validate the results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department of Xianyang Central Hospital, Xianyang, Shaanxi Province, 712000, PR China.
- Cardiovascular Hospital of the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi Province, 710016, PR China.
- Cardiology Department of Yangling Demonstration District Hospital, Xianyang, Shaanxi Province, 712100, PR China.
- Cardiology Department of Beijing Luhe Hospital of Capital Medical University, 101149, PR China.
Zitieren
APA
Fan, G., Zuo, H., Lin, L., Xu, C., & Yan, R. (2025). The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies. Global Heart, 20(1), 53. https://doi.org/10.5334/gh.1440
Vancouver
Fan G, Zuo H, Lin L, Xu C, Yan R. The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies. Global Heart. 2025;20(1):53. doi:10.5334/gh.1440
BibTeX
@article{Fan2025,
author = {Fan, Gang and Zuo, Hong and Lin, Lin and Xu, Chao and Yan, Rui},
title = {The Efficacy and Safety of Sodium Glucose Cotransporter 2 Inhibitors for Patients with Anticancer Therapy: A Meta-Analysis of Cohort Studies},
journal = {Global Heart},
year = {2025},
volume = {20},
number = {1},
pages = {53},
doi = {10.5334/gh.1440}
}
EUVIMED